Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Composition containing homoharringtonine as active ingredient for preventing or treating muscle diseases
US2024252510A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2024252510-A1 |
| Application number | US-202218563916-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 18, 2022 |
| Priority date | May 31, 2021 |
| Publication date | Aug 1, 2024 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a composition for preventing or treating muscle diseases, wherein the composition contains homoharringtonine as an active ingredient, wherein it was found that the suppression of a decrease in skeletal muscle mass and improved muscle strength were exhibited in an experimental group in which homoharringtonine was administered to an animal model in which reduction in muscle mass and muscular atrophy were induced by obesity, aging, or the fixing of lower extremities, and thus the composition including homoharringtonine as an active ingredient can be provided as a pharmaceutical composition or a health food for preventing or treating muscle diseases caused by a decrease in muscle mass or muscle strength.
First claim
Opening claim text (preview).
1 . A method of preventing or treating muscle diseases, comprising: administering a pharmaceutical composition comprising homoharringtonine as an active ingredient to a subject. 2 . The method of claim 1 , wherein the muscle disease is one or more selected from the group consisting of sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular weakness, muscular dystrophy, amyotrophic lateral sclerosis, and inflammatory myopathy. 3 . The method of claim 1 , wherein the pharmaceutical composition comprises 0.01 to 10 parts by weight of homoharringtonine with respect to a total of 100 parts by weight of the pharmaceutical composition. 4 . The method of claim 1 , wherein the homoharringtonine inhibits muscle loss and increases muscle strength without a change in body weight. 5 . A method of preventing or ameliorating muscle diseases, comprising: administering a health food comprising homoharringtonine as an active ingredient to a subject. 6 . The method of claim 5 , wherein the muscle disease is one or more selected from the group consisting of sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular weakness, muscular dystrophy, amyotrophic lateral sclerosis, and inflammatory myopathy.
Assignees
Inventors
Classifications
Drugs for disorders of the muscular or neuromuscular system · CPC title
- A61K31/55Primary
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
having an effect on regeneration or building of ligaments or muscles · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
using additives (addition of substantially indigestible substances A23L33/21) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2024252510A1 cover?
- The present invention relates to a composition for preventing or treating muscle diseases, wherein the composition contains homoharringtonine as an active ingredient, wherein it was found that the suppression of a decrease in skeletal muscle mass and improved muscle strength were exhibited in an experimental group in which homoharringtonine was administered to an animal model in which reduction…
- Who is the assignee on this patent?
- Univ Yeungnam Res Cooperation Foundation
- What technology area does this patent fall under?
- Primary CPC classification A61K31/55. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Aug 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).